Category: Hypersomnias

Hypersomnias

Treating Narcolepsy Around the Clock

New data suggest that targeting the underlying orexin deficiency can improve a broad spectrum of narcolepsy type 1 symptoms, from daytime cognition to nighttime sleep architecture.

Hypersomnias

New Pivotal Study Data Released for Takeda’s Oveporexton

New phase 3 data indicate that Takeda’s investigational orexin agonist, oveporexton, significantly improves daily functioning, cognition, and nighttime sleep in patients with narcolepsy type 1.

Hypersomnias

Alkermes Reports Positive Phase 3 Results for LUMRYZ in Idiopathic Hypersomnia

The REVITALYZ study met its primary endpoint, demonstrating significant improvements in excessive daytime sleepiness for adults with idiopathic hypersomnia treated with once-nightly LUMRYZ.

Narcolepsy

Alkermes Completes Acquisition of Avadel Pharmaceuticals, Adding LUMRYZ to Portfolio

The acquisition accelerates Alkermes’ entry into the sleep medicine market and incorporates the FDA-approved extended-release sodium oxybate treatment for narcolepsy.

Idiopathic Hypersomnia

FDA Grants Orphan Drug Designation to IH Drug Contender

A phase 3 trial is underway to evaluate the drug's efficacy and safety in adults with IH, with enrollment expected to complete by the end of 2025.

Insufficient Sleep Syndrome

Sleep Disorders and Lack of Sleep Plague Active US Military Personnel

A new study found that 85% of active duty servicemen and servicewomen have sleep disorders.

When Seizures Strike Sleep

Kleine-Levin Syndrome

Kleine-Levin Syndrome Foundation Taps First Executive Director

An experienced non-profit leader and author is appointed to the first-ever professional staff role for the foundation.